Product Description
Lactobacillus paracasei to reduce the GI and psychological symptoms of IBS
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nondrug
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: KGK Science Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Irritable Bowel Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02213172 |
14PIHL | P2 |
Completed |
Irritable Bowel Syndrome |
2018-02-15 |
2020-03-14 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|